MedPath

Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome

Phase 4
Recruiting
Conditions
Chronic Coronary Syndrome
Interventions
Drug: Yangxinshi tablet
Other: Basic medication
Registration Number
NCT06171061
Lead Sponsor
Shandong First Medical University
Brief Summary

This study is a prospective, multicentre, randomized, open-label, blinded-endpoint clinical trial to evaluate the efficacy and safety of Yangxinshi tablets in the treatment of patients with chronic coronary syndrome (CCS).

Detailed Description

This study plans to enrol 1200 CCS patients. A central randomized control group will be set up. The experimental and control groups will be populated at a 3:1 ratio. In addition to basic medication, the experimental group will be given Yangxinshi tablets (three tablets each time, three times a day); the control group will be given basic medication only. The treatment period is 24 weeks. The primary efficacy indicator is the 6-minute walking distance (6MWD).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1200
Inclusion Criteria
  1. age 18-75 years;
  2. CCS patients in stable condition and clearly diagnosed by coronary artery imaging (at least one vessel stenosis β‰₯ 50%): stable angina, ischaemic cardiomyopathy, asymptomatic or stable symptoms, occult coronary heart disease, acute coronary syndrome (ACS), or >3 months after coronary revascularization;
  3. moderately to severely limited exercise tolerance: the maximum 6MWD is < 450 m, or the metabolic equivalent (MET) as measured by treadmill cardiopulmonary exercise testing is < 5 METs;
  4. voluntary participation and signing of informed consent.
Exclusion Criteria
  1. absolute or relative contraindications for the treadmill cardiopulmonary exercise test or 6-minute walk test (6MWT);
  2. serious primary diseases, mental diseases, or malignant tumours that affect lifespan;
  3. pregnancy, intended or suspected pregnancy, miscarriage, breastfeeding, or delivery in the last 6 months;
  4. subjects not suitable for this study in the opinion of the researchers, such as subjects who are participating in other drug clinical trials or intervention studies.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental groupYangxinshi tabletbasic medication + Yangxinshi tablet
Control groupBasic medicationbasic medication.
Primary Outcome Measures
NameTimeMethod
6MWD24 weeks after treatment

The 6-min walking distance

Secondary Outcome Measures
NameTimeMethod
MACCEafter 4, 8, 12, 16, 20, and 24 weeks of treatment

incidence of major adverse cardiovascular and cerebrovascular events (MACCE)

Borg scale24 weeks after treatment

score range: 0\~10,higher scores mean a worse outcome.

Trial Locations

Locations (32)

Zhengzhou Seventh People's Hospital

πŸ‡¨πŸ‡³

Zhengzhou, Henan, China

Binzhou Medical University Hospital

πŸ‡¨πŸ‡³

Binzhou, Shandong, China

Binzhou People's Hospital

πŸ‡¨πŸ‡³

Binzhou, Shandong, China

Jinan Central Hospital

πŸ‡¨πŸ‡³

Jinan, Shandong, China

Longkou People Hosptial

πŸ‡¨πŸ‡³

Longkou, Shandong, China

Hospital of Cardiovascular Diseases Affiliated to Qingdao University

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

Shapingba District People's Hospital of Chongqing

πŸ‡¨πŸ‡³

Chongqing, Chongqing, China

Dezhou Municiple Hospital

πŸ‡¨πŸ‡³

Dezhou, Shandong, China

Feicheng People's Hospital

πŸ‡¨πŸ‡³

Feicheng, Shandong, China

Pingyuan County first People's Hospital

πŸ‡¨πŸ‡³

Dezhou, Shandong, China

Shandong Health Group Feicheng Hospital

πŸ‡¨πŸ‡³

Feicheng, Shandong, China

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

πŸ‡¨πŸ‡³

Jinan, Shandong, China

Jinan Zhangqiu District People's Hospital

πŸ‡¨πŸ‡³

Jinan, Shandong, China

Shandong Provincial Hospital Affiliated to Shandong First Medical University

πŸ‡¨πŸ‡³

Jinan, Shandong, China

The Fourth People's Hospital of Jinan

πŸ‡¨πŸ‡³

Jinan, Shandong, China

Gaotang County People's Hospital

πŸ‡¨πŸ‡³

Liaocheng, Shandong, China

Liaocheng Hospital of Traditional Chinese Medicine

πŸ‡¨πŸ‡³

Liaocheng, Shandong, China

Liaocheng People's Hospital

πŸ‡¨πŸ‡³

Liaocheng, Shandong, China

Linyi People's Hospital

πŸ‡¨πŸ‡³

Linyi, Shandong, China

The Second People's Hospital of Liaocheng

πŸ‡¨πŸ‡³

Liaocheng, Shandong, China

Linqing City People's Hospital

πŸ‡¨πŸ‡³

Linqing, Shandong, China

Affiliated Hospital of Qingdao University

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

Qingdao Fuwai Hospital

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

Qingdao Central Hospital

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

Qingdao Municipal Hospital

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

Shandong University Qilu Hospital Qingdao District

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

Xintai People's Hospital

πŸ‡¨πŸ‡³

Taian, Shandong, China

The Second Affiliated Hospital of Shandong First Medical University

πŸ‡¨πŸ‡³

Taian, Shandong, China

Weifang City People's Hospital

πŸ‡¨πŸ‡³

Weifang, Shandong, China

Tengzhou Central People's Hospital

πŸ‡¨πŸ‡³

Tengzhou, Shandong, China

Weifang City Yidu Central Hospital

πŸ‡¨πŸ‡³

Weifang, Shandong, China

Yantai Hospital of Traditional Chinese Medicine

πŸ‡¨πŸ‡³

Yantai, Shandong, China

Β© Copyright 2025. All Rights Reserved by MedPath